Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging

Hans Jürgen Wester; Ulrich Keller; Margret Schottelius; Ambros Beer; Kathrin Philipp-Abbrederis; Frauke Hoffmann; Jakub Šimeček; Carlos Gerngross; Michael Lassmann; Ken Herrmann; Natalia Pellegata; Martina Rudelius; Horst Kessler; Markus Schwaiger

doi:10.7150/thno.11251

Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging

Hans Jürgen Wester, Ulrich Keller, Margret Schottelius, Ambros Beer, Kathrin Philipp-Abbrederis, Frauke Hoffmann, Jakub Šimeček, Carlos Gerngross, Michael Lassmann, Ken Herrmann, Natalia Pellegata, Martina Rudelius, Horst Kessler, Markus Schwaiger

Default

Research output: Contribution to journal › Article › peer-review

165 Scopus citations

Abstract

Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [⁶⁸Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [⁶⁸Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [⁶⁸Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [⁶⁸Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.

Original language	English
Pages (from-to)	618-630
Number of pages	13
Journal	Theranostics
Volume	5
Issue number	6
DOIs	https://doi.org/10.7150/thno.11251
State	Published - 2015

Keywords

CXCR4
Chemokine receptor
Lymphoma, in vivo imaging
Positron emission tomography

Access to Document

10.7150/thno.11251

Cite this

Wester, H. J., Keller, U., Schottelius, M., Beer, A., Philipp-Abbrederis, K., Hoffmann, F., Šimeček, J., Gerngross, C., Lassmann, M., Herrmann, K., Pellegata, N., Rudelius, M., Kessler, H., & Schwaiger, M. (2015). Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics, 5(6), 618-630. https://doi.org/10.7150/thno.11251

@article{1cd35ea1f2384501831a5f29e9ea756f,

title = "Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging",

abstract = "Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [68Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [68Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [68Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [68Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.",

keywords = "CXCR4, Chemokine receptor, Lymphoma, in vivo imaging, Positron emission tomography",

author = "Wester, {Hans J{\"u}rgen} and Ulrich Keller and Margret Schottelius and Ambros Beer and Kathrin Philipp-Abbrederis and Frauke Hoffmann and Jakub {\v S}ime{\v c}ek and Carlos Gerngross and Michael Lassmann and Ken Herrmann and Natalia Pellegata and Martina Rudelius and Horst Kessler and Markus Schwaiger",

note = "Publisher Copyright: {\textcopyright} 2015 Ivyspring International Publisher.",

year = "2015",

doi = "10.7150/thno.11251",

language = "English",

volume = "5",

pages = "618--630",

journal = "Theranostics",

issn = "1838-7640",

publisher = "Ivyspring International Publisher",

number = "6",

}

Wester, HJ, Keller, U, Schottelius, M, Beer, A, Philipp-Abbrederis, K, Hoffmann, F, Šimeček, J, Gerngross, C, Lassmann, M, Herrmann, K, Pellegata, N, Rudelius, M, Kessler, H & Schwaiger, M 2015, 'Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging', Theranostics, vol. 5, no. 6, pp. 618-630. https://doi.org/10.7150/thno.11251

TY - JOUR

T1 - Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging

AU - Wester, Hans Jürgen

AU - Keller, Ulrich

AU - Schottelius, Margret

AU - Beer, Ambros

AU - Philipp-Abbrederis, Kathrin

AU - Hoffmann, Frauke

AU - Šimeček, Jakub

AU - Gerngross, Carlos

AU - Lassmann, Michael

AU - Herrmann, Ken

AU - Pellegata, Natalia

AU - Rudelius, Martina

AU - Kessler, Horst

AU - Schwaiger, Markus

PY - 2015

Y1 - 2015

N2 - Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [68Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [68Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [68Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [68Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.

AB - Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [68Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [68Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [68Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [68Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.

KW - CXCR4

KW - Chemokine receptor

KW - Lymphoma, in vivo imaging

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=84926192140&partnerID=8YFLogxK

U2 - 10.7150/thno.11251

DO - 10.7150/thno.11251

M3 - Article

C2 - 25825601

AN - SCOPUS:84926192140

SN - 1838-7640

VL - 5

SP - 618

EP - 630

JO - Theranostics

JF - Theranostics

IS - 6

ER -

Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this